Public Service Enterprise Group Incorporated (PEG)
NYSE: PEG · Real-Time Price · USD
83.11
+0.38 (0.46%)
At close: Oct 24, 2025, 4:00 PM EDT
83.02
-0.09 (-0.11%)
After-hours: Oct 24, 2025, 7:00 PM EDT
PEG Revenue
Public Service Enterprise Group had revenue of $2.81B in the quarter ending June 30, 2025, with 15.77% growth. This brings the company's revenue in the last twelve months to $11.13B, up 8.69% year-over-year. In the year 2024, Public Service Enterprise Group had annual revenue of $10.29B, down -8.43%.
Revenue (ttm)
$11.13B
Revenue Growth
+8.69%
P/S Ratio
3.72
Revenue / Employee
$853,376
Employees
13,047
Market Cap
41.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.29B | -947.00M | -8.43% |
| Dec 31, 2023 | 11.24B | 1.44B | 14.66% |
| Dec 31, 2022 | 9.80B | 78.00M | 0.80% |
| Dec 31, 2021 | 9.72B | 119.00M | 1.24% |
| Dec 31, 2020 | 9.60B | -473.00M | -4.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Duke Energy | 30.85B |
| The Southern Company | 28.36B |
| NextEra Energy | 25.90B |
| Constellation Energy | 24.82B |
| Exelon | 23.77B |
| National Grid | 23.74B |
| American Electric Power Company | 20.67B |
| Vistra | 18.51B |
PEG News
- 12 days ago - PSEG To Announce Third Quarter 2025 Financial Results On November 3 - PRNewsWire
- 4 weeks ago - PSEG Long Island to Continue Serving Long Island and the Rockaways for the Next Five Years - PRNewsWire
- 7 weeks ago - Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis - GlobeNewsWire
- 7 weeks ago - Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis - GlobeNewsWire
- 2 months ago - Public Service Enterprise: Long-Term Earnings Outlook Remains Very Positive - Seeking Alpha
- 2 months ago - Three Stocks Morgan Stanley Recommends for Playing the ‘Nuclear Renaissance' - Investopedia
- 2 months ago - Public Service Enterprise Group Incorporated (PEG) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - PSEG ANNOUNCES SECOND QUARTER 2025 RESULTS - PRNewsWire